WO2009103754A2 - Nouvelle utilisation de 3,3'-diindolylméthane - Google Patents

Nouvelle utilisation de 3,3'-diindolylméthane Download PDF

Info

Publication number
WO2009103754A2
WO2009103754A2 PCT/EP2009/051958 EP2009051958W WO2009103754A2 WO 2009103754 A2 WO2009103754 A2 WO 2009103754A2 EP 2009051958 W EP2009051958 W EP 2009051958W WO 2009103754 A2 WO2009103754 A2 WO 2009103754A2
Authority
WO
WIPO (PCT)
Prior art keywords
age
use according
dim
aging
loss
Prior art date
Application number
PCT/EP2009/051958
Other languages
English (en)
Other versions
WO2009103754A3 (fr
Inventor
Hubert Hug
Bernd Musselr
Daniel Raederstorff
Ying Wang-Schmidt
Original Assignee
Dsm Ip Assets B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dsm Ip Assets B.V. filed Critical Dsm Ip Assets B.V.
Publication of WO2009103754A2 publication Critical patent/WO2009103754A2/fr
Publication of WO2009103754A3 publication Critical patent/WO2009103754A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to a novel use of 3,3'-diindolylmethane (CAS 1968-05-4) and/or its derivatives; in particular it relates to the use of 3,3'-diindolylmethane and/or its derivatives in the form of a pharmaceutical and/or nutritional composition to retard or delay typical signs of aging and/or age-related pathological changes.
  • DIM 3,3'-diindolylmethane
  • I3C indole-3-carbinol
  • DIM has been shown to have several beneficial properties such as cardio and brain protective activities, cancer prevention, and benefits for perimenopausal women in premenstrual syndrome (PMS), endometriosis, and cervical dysplasia. Women on estrogen replacement (HRT) also benefit from DIM supplementation, as well as men with estrogen-related conditions, including prostate hypertrophy. I3C and DIM have also been shown to have multiple anti-cancer effects both in in-vivo and in-vitro models.
  • Mammalian aging is phenotypically characterized by hair loss, graying, wrinkles, general weight loss and abnormal spinal curvature (kyphosis).
  • General underlying mechanisms are the loss of the ability of specific cell division and apoptosis.
  • ROS Reactive oxygen species
  • O Y superoxide anion
  • H 2 O 2 hydrogen peroxide
  • OH hydroxyl radical
  • Endogenous, cellular enzymes such as catalase, copper/zinc and manganese superoxide dismutase (SOD1 and SOD2, respectively) and peroxidase convert ROS to neutral, non-reactive molecules. Accordingly these substances are important contributors to cellular stability and survival.
  • SOD1 and SOD2, respectively endogenous, cellular enzymes, such as catalase, copper/zinc and manganese superoxide dismutase (SOD1 and SOD2, respectively) and peroxidase convert ROS to neutral, non-reactive molecules. Accordingly these substances are important contributors to cellular stability and survival.
  • SOD1 and SOD2 manganese superoxide dismutase
  • mice carrying a homozygous mutation leading to a defect in the proofreading function of mitochondrial DNA polymerase- ⁇ show typical hallmarks of accelerated aging (Trifunovic et al., Nature 429, 417-423, 2004; Kujoth et al., Science 309, 481-484, 2005; Mouse model for aging, US Patent No. 60/663930, 2005). It has been suggested that - instead of reactive oxygen induced damage - mitochondrial respiratory chain dysfunction is the primary inducer of premature aging in these mice (Trifunovic et al., PNAS 102, 17993-17998, 2005).
  • NDCD National Institute of Deafness and Other Communication Disorders
  • hearing loss occurs. Structural changes in the inner ear, such as the degeneration of sensory cells, auditory neurons and cells of the stria vascularis, also contribute to hearing loss.
  • the cochlear degeneration can be attributed to the accumulated effects of numerous insults including exposure to acoustic trauma and ototoxic drugs.
  • hearing loss is a common phenomenon in mammals, regardless of noise and toxin exposure.
  • hereditary factors, blood supply dysfunction due to heart disease, high blood pressure, diabetes, or other circulatory problems are all risk factors leading to hearing loss.
  • magnesium deficiency can increase the stress on cells involved with hearing and thereby make them more susceptible to damage caused by intense noise.
  • human magnesium deficiency is rare, so it is possible that supplemental magnesium acts in some entirely different way.
  • Ginkgo extract was used to treat sudden hearing loss, or so called unilateral idiopathic sudden hearing loss. Ginkgo extract, which is shown to improve circulation, has been tested as treatment for the sudden hearing loss. In a double-blind study, ginkgo was compared to pentoxifylline, a circulation-enhancing drug used in Germany for the treatment of sudden hearing loss and the results indicate that ginkgo was at least as effective as the medication.
  • Antioxidant supplementation was suggested as promising measures for hearing loss prevention, and commonly used antioxidants are citrus bioflavonoids, coenzyme Q10, lipoic acid, lutein, lycopene, oligomeric proanthocyanidins (OPCs), vitamin C and vitamin E.
  • OPCs oligomeric proanthocyanidins
  • Sarcopenia is the degenerative loss of skeletal muscle mass and strength in senescence. About a third of muscle mass is lost in old age. The level of sarcopenia can be so severe that it prevents an elderly person from living an independent life and they require constant assistance and care. Sarcopenia is an important independent predictor of disability in population-based studies, linked to poor balance, gait speed, falls, and fractures.
  • the object of the present invention is achieved by a composition for the retard or delay of typical signs of aging and/or age-related pathological changes in mammals characterized in that the composition contains 3,3'-diindolylmethane.
  • 3,3'-diindolylmethane and “DIM” as used herein also include derivatives of 3,3'-diindolylmethane according to the following chemical structure:
  • R1 H, OCH 3 , CH 3 with the provisio that at least 3 of the 5 residues R1 are H;
  • 3,3'-diindolylmethane may be of synthetic origin or it may be isolated from plant extracts, such as extracts of cruciferous vegetables (including their seeds and/or sprouts). It may also be advantageous to use extracts containing 3,3'- diindolylmethane, for example extracts obtainable from cruciferous vegetables. Based on the particular extraction procedure the amount of phenolic compounds in a plant extract can be easily adjusted by a person skilled in the art. It is preferred if the amount of 3,3'- diindolylmethane in a plant extract according to the present invention is in the range of from 20 to 80 % by weight, more preferred from 30 to 50 % by weight, each based on the total weight of the extract.
  • Balance or one's sense of equilibrium, is controlled through the vestibular system that is also contained in the inner ear.
  • the vestibular organs share the temporal bone space with the cochlea. These organs also share the same fluid that is in the cochlea.
  • Balance and equilibrium help us stay erect when standing, know where we are in relation to gravity, and help us walk, run, and move without falling.
  • the functioning of the vestibular system depends on information from many systems, hearing as well as vision and muscle feedback. Problems with balance occur whenever there is a disruption in any of the vestibular, visual, proprioceptive or cognitive systems.
  • Symptoms of a balance disorder may include dizziness, vertigo (spinning), disequilibrium (off balance and falls), pre-syncope (light headedness). Many different terms are often used to describe what is collectively known as dizziness. Common descriptions include words such as lightheaded, floating, whoozy, giddy, confused, helpless or fuzzy. Vertigo, Disequilibrium and Pre-syncope are the terms in use by most doctors.
  • the present invention relates to the use of 3,3'-diindolylmethane to hinder and/or reduce (age-related) loss of balance and/or dizziness, and to the use of 3,3'- diindolylmethane in the manufacture of a composition such as a food or beverage, or a supplement for food or beverage, for hindering and/or reducing (age-related) loss of balance and/or dizziness.
  • a composition such as a food or beverage, or a supplement for food or beverage
  • Wellness denotes the general state of physical and mental health of an organism, especially when maintained by proper diet; exercise and habits (see The American Heritage® Stedman's Medical Dictionary, publ. Houghton Mifflin Co, 2002). However, the pre-conditions for maintaining the wellness state are not always fulfilled in today's population.
  • the term "wellness state” as used herein denotes to the actual state of physical and mental health of an individual and may therefore vary from being completely healthy to being completely ill and can accordingly be promoted any time when it differs from being completely healthy.
  • the wellness state can be determined, inter alias, by evaluating parameters (body functions) such as blood pressure, heart rate, body fat composition, pulmonary function, liver function, brain function and levels of physiologically vital components in body fluids etc. as e.g. disclosed in US patent 5,692,501.
  • Mobility denotes the general state of being able to move and accordingly live an independent life without the need of constant assistance and care.
  • the present invention relates to the use of 3,3'-diindolylmethane to promote the wellness state of a mammal, and to the use of 3,3'-diindolylmethane in the manufacture of a composition such as a food or beverage, or a supplement for food or beverage, for promoting the wellness state of a mammal.
  • a composition such as a food or beverage, or a supplement for food or beverage
  • composition according to the invention is preferably a dietary supplement, a food or feed additive, a functional food or feed, a food or feed premix, and/or a beverage.
  • mammals are preferably humans, the invention is not limited to humans but includes other mammals, such as dromedaries, camels, elephants, and horses and pets such as dogs, cats and/or small animals.
  • 3,3'-diindolylmethane may be administered to, e.g., a human adult (weighing about 70 kg) in an amount of up to about 10 to 1000 mg/day in one or several dosage units or servings.
  • the dosage for a human adult (weighing about 70 kg) is up to about 500 mg/day, especially up to about 30 to 300 mg/day.
  • the amount of DIM contained therein is suitably no less than about 100 mg per serving.
  • DIM is administered as a pharmaceutical formulation such formulation may contain up to about 500 mg per solid dosage unit, e.g. per capsule.
  • serving denotes an amount of food and/or beverage normally ingested by a human adult with a meal at a time and may range, e.g., from about 100 g to about 500 g food and/or beverage.
  • composition according to the present invention can preferably be a nutraceutical composition.
  • nutraceutical as used herein denotes usefulness in both, the nutritional and pharmaceutical field of application.
  • “nutraceutical compositions” according to the present invention can serve as supplements to food, feed and beverages, dietary supplements and as pharmaceutical formulations which may be solid - such as capsules - or liquid - such as solutions or suspensions. It is evident from the foregoing that the term “nutraceutical composition” also comprises food, feed and beverages containing DIM.
  • a multi-vitamin and mineral supplement may be added to the compositions according to the present invention, e.g. to maintain a good balanced nutrition or to obtain an adequate amount of an essential nutrient missing in some diets.
  • the multi-vitamin and mineral supplement may also be useful for disease prevention and protection against nutritional losses and deficiencies due to lifestyle patterns and common inadequate dietary patterns sometimes observed in diabetes.
  • the composition according to the present invention can be a food or beverage composition.
  • Beverages can be e.g. sports drinks, energy drinks or other soft drinks, or any other suitable beverage preparation, e.g. yoghurt drinks, hot beverages or soups.
  • the beverage is an "instant beverage", i.e. a beverage which is produced - normally by the consumer themselves - by stirring a powder into a liquid, usually milk or water.
  • sports drink a beverage is meant which is consumed before, during and/or after physical exercise, mainly to hydrate as well as to (re-) store electrolytes, sugar and other nutrients.
  • Sports drinks are usually isotonic, meaning they contain the same proportions of nutrients as found in the human body.
  • Energy drinks are beverages which contain (legal) stimulants, vitamins (especially B vitamins) and/or minerals with the intent to give the user a burst of energy.
  • Common ingredients include caffeine, guarana (caffeine from the Guarana plant) and/or taurine, various forms of ginseng, maltodextrin, inositol, carnitine, creatine, glucuronolactone, coenzyme Q10 and/or ginkgo biloba.
  • Some may contain high levels of sugar, or glucose, whereas others are sweetened completely or partially with a sugar alcohol and/or an artificial sweetener like Ca-cyclamate or Aspartame. Many such beverages are flavored and/or colored.
  • a soft drink is a drink that does not contain alcohol.
  • the term is used only for cold beverages. Hot chocolate, tea, and coffee are not considered soft drinks.
  • the term includes carbonated and non-carbonated drinks, e.g. mineral water or so-called “near water drinks", i.e. water-based beverages which have an additional benefit, e.g. a special flavor and/or further (functional) ingredients.
  • a "near water drink” is a mixture of water with very little juice.
  • Figure 1 shows the effect of DIM on total body weights in D257A mice. Each bar represents the average of at least 4 independent mice + SEM. The y-axis shows the body weight in g. Black bars represent male, grey bars female mice. Values are shown for: I: Control; II: DIM;
  • Figure 2 shows the effect of DIM on femur bone mineral density in female D257A mice (y- axis in mg/cm 2 ). Each bar represents the average of 4 independent mice + SEM. Values are shown for: I: Control; II: DIM;
  • Figure 3 shows the effect of DIM on gastrocnemius weights in D257A mice (y-axis in mg).
  • the male control represents the average of 2 mice, the female control of 3 mice + SEM;
  • DIM treatment represents the average of 6 male mice + SEM and 2 female mice. Values are shown for: I: Control;
  • Figure 4 shows the effect of several compounds on age related hearing loss (presbycusis) in D257A mice, an accelerated ageing mouse model, which exhibit significantly reduced hearing function.
  • the auditory-evoked brain stem response threshold in decibels (dB) 8 kHz is shown on the y-axis. Black circles represent male, grey circles female D257A mice. ⁇ means that no response was obtained. Values are shown for: I: Control;
  • the efficacy of DIM was demonstrated as shown by tests set forth below.
  • the test system was D257A-/- (D257A) mice that express a proofreading-deficient version of the mitochondrial DNA polymerase ⁇ (POLG). These mice display features of accelerated aging including a decrease in body weight, hair graying, decrease in bone mineral density (BMD), muscle loss and age related hearing loss (Kujoth et al., Science 309, 481-484, 2005).
  • D257A mice Heterozygous D257A (-/+) mice were bred to generate homozogous D257A (-/-) mice, denoted D257A hereafter. Animals were identified with specific numbering and ear clippings. D257A mice were placed in various dietary regimens following PCR based genotyping and weaning at 3 weeks of age. Mice received a diet based on AIN-93M maintenance purified diet (TestDiet, Richmond, USA), with neither no supplementation (Control group), or supplementation with DIM (40 mg/kg, BioResponse LLC Boulder, CO).
  • the body weight of all surviving D257A mice was determined at 9 months of age.
  • Gastrocnemius weights were determined from the surviving D257A mice at 9 months of age following euthanasia to a standard necropsy protocol.
  • ABRs Auditory brainstem responses
  • Animals were anesthetized with a mixture of xylazine hydrochloride (10 mg/kg, i.m.) and ketamine hydrochloride (40 mg/kg, i.m.), and needle electrodes were placed subcutaneously at the vertex (active electrode), beneath the pinna of the measured ear (reference electrode), and beneath the opposite ear (ground).
  • the stimulus duration, presentation rate, and rise/fall time was 3 ms, 19.3/s, and 1 ms respectively.
  • Weight loss is a general hallmark of the late stages of aging in mammalians. Therefore, we first looked for changes in total body weights of the D257A mice treated with DIM and other compounds in comparison to untreated control. DIM treated male D257A mice tended to have a higher total body weight compared to controls treated mice (Fig. 1 ). Aging in rodents and humans is characterized by loss of muscle mass (sarcopenia).
  • D257A mice displayed age related loss of skeletal muscle (Kujoth et al., Science 309, 481- 484, 2005). Therefore, we tested whether DIM could inhibit age related muscle loss.
  • Soft gelatin capsules are prepared by conventional procedures containing as active ingredient 100 to 200 mg of DIM per capsule.
  • Hard gelatin capsules are prepared by conventional procedures containing as active ingredient 100 to 200 mg of DIM per capsule.
  • Example 3 Food items may be prepared by conventional procedures containing DIM in an amount of 10 mg to 400 mg per serving.
  • Examples of such food items are soft drinks, bread, cookies, yoghurt, ice cream, and sweets.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Botany (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Indole Compounds (AREA)

Abstract

L'invention concerne une nouvelle utilisation de 3,3'-diindolylméthane (CAS1968-05-4) et/ou de ses dérivés sous la forme d'une composition pharmaceutique et/ou nutritionnelle pour retarder ou différer les signes caractéristiques du vieillissement et/ou les changements pathologiques liés à l'âge.
PCT/EP2009/051958 2008-02-19 2009-02-19 Nouvelle utilisation de 3,3'-diindolylméthane WO2009103754A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08003003.4 2008-02-19
EP08003003 2008-02-19

Publications (2)

Publication Number Publication Date
WO2009103754A2 true WO2009103754A2 (fr) 2009-08-27
WO2009103754A3 WO2009103754A3 (fr) 2009-11-12

Family

ID=40983389

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/051958 WO2009103754A2 (fr) 2008-02-19 2009-02-19 Nouvelle utilisation de 3,3'-diindolylméthane

Country Status (1)

Country Link
WO (1) WO2009103754A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012130698A1 (fr) 2011-03-25 2012-10-04 Iiaa Limited Composition comprenant un di-indolylméthane et un rétinoïde pour le traitement d'une affection cutanée
GB2528482A (en) * 2014-07-23 2016-01-27 Skintech Life Science Ltd Pharmaceutical agent
WO2018128481A1 (fr) * 2017-01-06 2018-07-12 연세대학교 산학협력단 Composition destinée à la prévention ou au traitement de maladies musculaires, comprenant comme principe actif de l'indole-3-carbinol ou un sel pharmaceutiquement acceptable de celui-ci
WO2021254752A1 (fr) * 2020-06-19 2021-12-23 Unilever Ip Holdings B.V. Utilisation de composés de diindolylméthane pour traiter les signes du vieillissement cutané

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999049851A1 (fr) * 1998-04-01 1999-10-07 Bioresponse, L.L.C. Systeme d'apport d'elements nutritifs
WO2001020991A1 (fr) * 1999-09-23 2001-03-29 Bioresponse L.L.C. Produits phytochimiques favorisant la perte de poids
JP2003081848A (ja) * 2001-09-13 2003-03-19 Maruzen Pharmaceut Co Ltd 活性酸素消去剤、該活性酸素消去剤を配合した化粧料及び飲食物
WO2003034992A2 (fr) * 2001-10-23 2003-05-01 Bioresponse, L.L.C. Di-indolylmethane pour le traitement d'infections par le papillomavirus humain
WO2006105196A2 (fr) * 2005-03-28 2006-10-05 Bioresponse, L.L.C. Compositions a base de diindolylmethane et leurs procedes d'utilisation pour favoriser la sante de la muqueuse buccale et la sante des os
WO2007096886A2 (fr) * 2006-02-27 2007-08-30 Lycored Ltd. Composition et procédés de traitement et de prévention de la dégénérescence maculaire liée à l'âge

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999049851A1 (fr) * 1998-04-01 1999-10-07 Bioresponse, L.L.C. Systeme d'apport d'elements nutritifs
WO2001020991A1 (fr) * 1999-09-23 2001-03-29 Bioresponse L.L.C. Produits phytochimiques favorisant la perte de poids
JP2003081848A (ja) * 2001-09-13 2003-03-19 Maruzen Pharmaceut Co Ltd 活性酸素消去剤、該活性酸素消去剤を配合した化粧料及び飲食物
WO2003034992A2 (fr) * 2001-10-23 2003-05-01 Bioresponse, L.L.C. Di-indolylmethane pour le traitement d'infections par le papillomavirus humain
WO2006105196A2 (fr) * 2005-03-28 2006-10-05 Bioresponse, L.L.C. Compositions a base de diindolylmethane et leurs procedes d'utilisation pour favoriser la sante de la muqueuse buccale et la sante des os
WO2007096886A2 (fr) * 2006-02-27 2007-08-30 Lycored Ltd. Composition et procédés de traitement et de prévention de la dégénérescence maculaire liée à l'âge

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AGGARWAL BHARAT B ET AL: "Molecular targets and anticancer potential of indole-3-carbinol and its derivatives." CELL CYCLE (GEORGETOWN, TEX.) SEP 2005, vol. 4, no. 9, September 2005 (2005-09), pages 1201-1215, XP008087499 ISSN: 1551-4005 *
GONG YIXUAN ET AL: "3,3'-Diindolylmethane is a novel mitochondrial H(+)-ATP synthase inhibitor that can induce p21(Cip1/Waf1) expression by induction of oxidative stress in human breast cancer cells." CANCER RESEARCH 1 MAY 2006, vol. 66, no. 9, 1 May 2006 (2006-05-01), pages 4880-4887, XP002545928 ISSN: 0008-5472 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012130698A1 (fr) 2011-03-25 2012-10-04 Iiaa Limited Composition comprenant un di-indolylméthane et un rétinoïde pour le traitement d'une affection cutanée
JP2014508793A (ja) * 2011-03-25 2014-04-10 アイアイエーエー リミテッド ジインドリルメタン及びレチノイドを含む皮膚症状を治療するための組成物
US9180117B2 (en) 2011-03-25 2015-11-10 Skintech Life Science Limited Composition comprising a diindolylmethane and a retinoid to treat a skin condition
US9351958B2 (en) 2011-03-25 2016-05-31 Skintech Life Science Limited Composition comprising a diindolylmethane and a retinoid to treat a skin condition
US9907785B2 (en) 2011-03-25 2018-03-06 Skintech Life Science Limited Composition comprising a diindolylmethane and a retinoid to treat a skin condition
US10500189B2 (en) 2011-03-25 2019-12-10 Skintech Life Sciences Limited Composition comprising a diindolylmethane and a retinoid to treat a skin condition
US10966958B2 (en) 2011-03-25 2021-04-06 Skintech Life Science Limited Composition comprising a diindolylmethane and a retinoid to treat a skin condition
US11911365B2 (en) 2011-03-25 2024-02-27 Skintech Life Science Limited Composition comprising a diindolylmethane and a retinoid to treat a skin condition
GB2528482A (en) * 2014-07-23 2016-01-27 Skintech Life Science Ltd Pharmaceutical agent
WO2018128481A1 (fr) * 2017-01-06 2018-07-12 연세대학교 산학협력단 Composition destinée à la prévention ou au traitement de maladies musculaires, comprenant comme principe actif de l'indole-3-carbinol ou un sel pharmaceutiquement acceptable de celui-ci
WO2021254752A1 (fr) * 2020-06-19 2021-12-23 Unilever Ip Holdings B.V. Utilisation de composés de diindolylméthane pour traiter les signes du vieillissement cutané

Also Published As

Publication number Publication date
WO2009103754A3 (fr) 2009-11-12

Similar Documents

Publication Publication Date Title
US8901109B2 (en) Quercetin-containing compositions
CN101484158B (zh) 衰老抑制剂
KR20080030633A (ko) 스트레스의 치료 또는 처치방법
AU2011354301B2 (en) Refreshing beverage
ES2710750T3 (es) Composición utilizada para mejorar la densidad del pigmento macular en los ojos y prevenir o tratar la degeneración macular relacionada con la edad
AU2003282829B2 (en) Antioxidative Compositions
JP2010524876A (ja) 老化防止剤としてのヒドロキシチロソールの使用
WO2009103754A2 (fr) Nouvelle utilisation de 3,3'-diindolylméthane
US8420677B2 (en) Use of 3,3′-diindolylmethane
EP1802298A2 (fr) Nouveaux agents de prevention et de traitement de troubles associes a une neurotransmission deficiente
US20100113612A1 (en) Novel use of hydroxytyrosol and olive extracts/concentrate containing it
JP2013249260A (ja) 老化抑制剤
JP2015063507A (ja) 老化に起因する網膜障害の抑制剤
KR100540498B1 (ko) 아스타잔틴 및 아스파라긴산을 함유하는 숙취해소제
Bawazir Impact of mix food colors with Barley Water (Talbina) on some neurotransmitters in different brain region biochemical and histological structure of liver male albino rats
US9844228B2 (en) Spray method and composition for reducing psychological hunger
WO2023056885A1 (fr) Méthode et composition d'imitation de la restriction calorique par administration d'ergothionéine
JP2004248659A (ja) 栄養素強化緑茶粉末
KR100777351B1 (ko) 발아 쥐눈이콩 추출물을 유효성분으로 함유하는 골다공증 예방 또는 치료용 건강식품
SH et al. Development and characterisation of a multifunctional hybrid nano-flora composite for the prevention and management of cancer, diabetes, blood pressure and stroke
MX2007002463A (es) Preparado de hierro ionico y hierro heminico y sus variantes en la profilaxis y tratamiento de la deficiencia de hierro.
PT1437051E (pt) Ocuvite lutein
JP2022010027A (ja) 網膜保護組成物
KR100505764B1 (ko) 아스타잔틴, 아스파라긴산 및 갈화 추출액을 함유하는숙취해소제
JP2022028067A (ja) 網膜保護組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09711715

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09711715

Country of ref document: EP

Kind code of ref document: A2